Hepatology Research最新文献

{"title":"Serum pro-inflammatory cytokine interleukin-6 level is predictive of further decompensation and mortality in liver cirrhosis","authors":"Yuji Ikeda,&nbsp;Hiroki Nago,&nbsp;Masahiro Yamaguchi,&nbsp;Rihwa Om,&nbsp;Yuichiro Terai,&nbsp;Yuji Kita,&nbsp;Sho Sato,&nbsp;Ayato Murata,&nbsp;Shunsuke Sato,&nbsp;Yuji Shimada,&nbsp;Akihito Nagahara,&nbsp;Takuya Genda","doi":"10.1111/hepr.14175","DOIUrl":"https://doi.org/10.1111/hepr.14175","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>Systemic inflammation drives the progression of portal hypertension in patients with liver cirrhosis. Interleukin-6 is a key mediator of the cytokine network in acute inflammation that stimulates the production of many acute phase reactants. In this study, we investigated the association between serum interleukin-6 and acute phase reactant levels and the disease stage and prognosis of patients with liver cirrhosis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A single-center retrospective cohort of 359 patients with liver cirrhosis was staged according to the symptomatic decompensation. Baseline serum C-reactive protein , interleukin-6, procalcitonin, and serum amyloid A protein levels were measured. The outcomes of further decompensation, hepatocellular carcinoma development, and mortality were identified during a 3.3-year median follow-up period.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Serum C-reactive protein , interleukin-6, and procalcitonin levels were significantly different across the stages. The multivariate Cox proportional hazards model identified serum interleukin-6 as an independent predictor of further decompensation in patients with compensated and the first single decompensated cirrhosis. Kaplan–Meier analyses showed that the probability of further decompensation was stratified by serum interleukin-6 level in a dose-dependent manner. In the entire cohort, serum interleukin-6 level also showed a significant association with liver-related and all-cause mortalities, but not with hepatocellular carcinoma development, independent of stage and liver disease severity indices.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Elevated levels of serum markers of systemic inflammation were associated with symptomatic decompensation, and serum interleukin-6 level is a predictor of further decompensation and mortality in patients with liver cirrhosis.</p>\u0000 </section>\u0000 </div>","PeriodicalId":12987,"journal":{"name":"Hepatology Research","volume":"55 5","pages":"696-706"},"PeriodicalIF":3.9,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143902830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Metabolic dysfunction-associated steatotic liver disease is a risk factor for gallstones: A multicenter cohort study","authors":"Tomonori Cho,&nbsp;Shuhei Fukunaga,&nbsp;Daiki Ohzono,&nbsp;Hiroshi Tanaka,&nbsp;Shinpei Minami,&nbsp;Tomoyuki Nakane,&nbsp;Michita Mukasa,&nbsp;Shinobu Yoshinaga,&nbsp;Ryuichi Nouno,&nbsp;Hidetoshi Takedatsu,&nbsp;Takumi Kawaguchi","doi":"10.1111/hepr.14170","DOIUrl":"https://doi.org/10.1111/hepr.14170","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>Gallstone formation is associated with metabolic dysfunction. Recently, new definitions of steatotic liver disease (SLD) have been proposed, including metabolic dysfunction-associated SLD (MASLD) and moderate alcohol intake (MetALD). We investigated the effects of MASLD/MetALD on gallstone formation.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This multicenter observational cohort study enrolled 8766 consecutive health-check examinees who underwent abdominal ultrasonography between 2008 and 2021 (total observation period 39,105.9 person-years). All patients were classified into non-SLD, MASLD, or MetALD groups. The effect of MASLD on gallstone development was evaluated using multivariate Cox regression analysis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Age, male sex, and MASLD were identified as independent risk factors for gallstone development. MASLD was associated with a significantly higher risk of developing gallstones than non-SLD (hazard ratio [HR] 1.7112; 95% confidence interval [CI] 1.4294–2.0486; <i>p</i> &lt; 0.0001) and MetALD (HR 1.3516, 95% CI 1.0130–1.8033, <i>p</i> = 0.0406). However, the risk of MetALD did not significantly differ between the SLD and non-SLD groups. Hypertension was the only significant independent cardiometabolic risk factor for gallstone development in the MASLD group (HR 1.4350, 95% CI 1.0545–1.9528; <i>p</i> = 0.0216). Random forest analysis and directed acyclic graphs identified hypertension as the most important direct factor affecting gallstone development in patients with MASLD.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>MASLD was an independent risk factor for gallstone development, whereas MetALD presented a similar risk as non-SLD. Moderate alcohol consumption may reduce the risk of gallstone formation in patients with MASLD. Hypertension may be the most significant cardiometabolic risk factor for gallstone development in patients with MASLD.</p>\u0000 </section>\u0000 </div>","PeriodicalId":12987,"journal":{"name":"Hepatology Research","volume":"55 5","pages":"663-674"},"PeriodicalIF":3.9,"publicationDate":"2025-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143902827","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of the revised Japanese indication criteria for deceased donor liver transplantation on liver cirrhotic patients of Child–Pugh classification B with hepatocellular carcinoma","authors":"Akihiro Seki,&nbsp;Tatsuya Yamashita,&nbsp;Takeshi Terashima,&nbsp;Shinichi Nakanuma,&nbsp;Mitsuyoshi Okazaki,&nbsp;Hidenori Kido,&nbsp;Masaki Nishitani,&nbsp;Masaki Miyazawa,&nbsp;Noboru Takata,&nbsp;Tomoyuki Hayashi,&nbsp;Hidetoshi Nakagawa,&nbsp;Rika Horii,&nbsp;Kouki Nio,&nbsp;Shinya Yamada,&nbsp;Hajime Takatori,&nbsp;Tetsuro Shimakami,&nbsp;Masao Honda,&nbsp;Shintaro Yagi,&nbsp;Taro Yamashita","doi":"10.1111/hepr.14168","DOIUrl":"https://doi.org/10.1111/hepr.14168","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>This study aimed to evaluate the impact of the revised deceased donor liver transplantation (DDLT) criteria on hepatocellular carcinoma (HCC) patients newly eligible under the Child–Pugh classification B (CP-B), by focusing on the prognosis and the risk of HCC recurrence beyond the Japan criteria while on the waiting list.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A retrospective analysis was carried out on 1155 patients diagnosed with HCC at Kanazawa University Hospital between 2006 and 2021. Prognosis and recurrence were analyzed for patients eligible for DDLT under the revised criteria.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Of the 1155 patients, 57 (4.9%) were eligible for DDLT according to the revised criteria. Five patients who underwent liver transplantation had a better prognosis compared to others who received treatments like radiofrequency ablation and transcatheter arterial chemoembolization. Patients with Child–Pugh score (CP) score of 7, a single tumor, and low des-γ-carboxy prothrombin (DCP) levels had favorable outcomes without transplantation, although long-term survival was superior with transplantation. However, 27.5% of eligible patients experienced recurrence or death within 30 months, which might disqualify them from DDLT. A scoring algorithm was developed based on CP score ≥8, multiple tumors, and DCP &gt; 100 IU/dL. Patients with scores of 1 or 2 had 5-year survival rates of 40% and 30%, respectively, and most would meet the Japan criteria after 30 months. For patients with a score of 3, living donor liver transplantation should be prioritized.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The revised DDLT criteria improve access to transplantation for CP-B patients with HCC, but the risk of progression or recurrence during the waiting period remains. Careful evaluation, bridging therapies, and continuous assessment are crucial for optimal outcomes.</p>\u0000 </section>\u0000 </div>","PeriodicalId":12987,"journal":{"name":"Hepatology Research","volume":"55 5","pages":"763-772"},"PeriodicalIF":3.9,"publicationDate":"2025-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/hepr.14168","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143902826","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of time-of-day atezolizumab plus bevacizumab combination therapy infusion for unresectable hepatocellular carcinoma: A retrospective multicenter study","authors":"Atsushi Naganuma,&nbsp;Satoru Kakizaki,&nbsp;Takeshi Hatanaka,&nbsp;Atsushi Hiraoka,&nbsp;Toshifumi Tada,&nbsp;Masashi Hirooka,&nbsp;Kazuya Kariyama,&nbsp;Joji Tani,&nbsp;Masanori Atsukawa,&nbsp;Koichi Takaguchi,&nbsp;Ei Itobayashi,&nbsp;Shinya Fukunishi,&nbsp;Kunihiko Tsuji,&nbsp;Toru Ishikawa,&nbsp;Kazuto Tajiri,&nbsp;Hidenori Toyoda,&nbsp;Yuichi Koshiyama,&nbsp;Chikara Ogawa,&nbsp;Hiroki Nishikawa,&nbsp;Takashi Nishimura,&nbsp;Kazuhito Kawata,&nbsp;Hisashi Kosaka,&nbsp;Kosuke Matsui,&nbsp;Yutaka Yata,&nbsp;Hironori Tanaka,&nbsp;Hideko Ohama,&nbsp;Hidekatsu Kuroda,&nbsp;Tomomitsu Matono,&nbsp;Tomoko Aoki,&nbsp;Hironori Ochi,&nbsp;Michitaka Imai,&nbsp;Shinichiro Nakamura,&nbsp;Yuki Kanayama,&nbsp;Kazunari Tanaka,&nbsp;Fujimasa Tada,&nbsp;Osamu Yoshida,&nbsp;Kazuhiro Nouso,&nbsp;Asahiro Morishita,&nbsp;Akemi Tsutsui,&nbsp;Takuya Nagano,&nbsp;Norio Itokawa,&nbsp;Tomomi Okubo,&nbsp;Taeang Arai,&nbsp;Hirayuki Enomoto,&nbsp;Masaki Kaibori,&nbsp;Yoichi Hiasa,&nbsp;Masatoshi Kudo,&nbsp;Takashi Kumada,&nbsp;the Real-life Practice Experts for HCC (RELPEC) Study Group, and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan)","doi":"10.1111/hepr.14171","DOIUrl":"https://doi.org/10.1111/hepr.14171","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>This study aimed to evaluate the impact of infusion timing of time-of-day on clinical outcomes in patients with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab combination therapy.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A retrospective analysis was conducted using data from 751 unresectable HCC patients treated with atezolizumab plus bevacizumab between September 2020 and April 2024. Patients were categorized into morning (AM; <i>n</i> = 351) and afternoon (PM; <i>n</i> = 400) groups based on infusion timing of time-of-day. Outcomes, including progression-free survival (PFS), overall survival, objective response rate, and disease control rate, were assessed using Kaplan–Meier survival analysis and Cox regression analysis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The PFS was significantly longer in the AM group (8.6 months, 95% CI 7.6–10.5) compared with the PM group (6.0 months, 95% CI 5.4–7.0; <i>p</i> = 0.006). In contrast, overall survival was similar between the groups (AM: 24.7 months vs. PM: 21.4 months; <i>p</i> = 0.99). Cox regression analysis revealed that morning infusion was an independent favorable predictor of PFS (HR 1.23, 95% CI 1.04–1.45). Additionally, the AM group demonstrated superior objective response rate and disease control rate compared with the PM group, suggesting better tumor control.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Morning infusion of atezolizumab plus bevacizumab is associated with improved PFS and response rates in unresectable HCC patients, highlighting the potential for optimizing treatment outcomes through circadian timing.</p>\u0000 </section>\u0000 </div>","PeriodicalId":12987,"journal":{"name":"Hepatology Research","volume":"55 5","pages":"741-751"},"PeriodicalIF":3.9,"publicationDate":"2025-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143902828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of hepatitis B virus genotype B and C patients in Japan in terms of family history and maternal age at birth","authors":"Kosuke Sato,&nbsp;Jun Inoue,&nbsp;Takehiro Akahane,&nbsp;Tomoo Kobayashi,&nbsp;Masashi Ninomiya,&nbsp;Akitoshi Sano,&nbsp;Mio Tsuruoka,&nbsp;Masazumi Onuki,&nbsp;Satoko Sawahashi,&nbsp;Keishi Ouchi,&nbsp;Kotaro Doi,&nbsp;Kengo Watanabe,&nbsp;Hirofumi Niitsuma,&nbsp;Atsushi Masamune","doi":"10.1111/hepr.14169","DOIUrl":"https://doi.org/10.1111/hepr.14169","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>Hepatitis B virus of genotypes B (HBV/B) and C (HBV/C) prevails in Japan and patients with HBV/B have been known to be older than those with HBV/C, but the reason has remained unknown. We aimed to clarify the reason by focusing on the family history of HBV infection.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>In a total of 508 patients with chronic HBV infection, HBV genotype, patient age, and age of the mother at birth were compared.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Patient age was significantly older in HBV/B than in HBV/C, and the patient percentage with a family history of HBV infection was lower in HBV/B. When comparing maternal age at birth between the two genotypes, there was no significant difference in the overall patient population, but the proportion of older birth group (≥26 years old) was significantly lower in HBV/B (38.7% vs. 59.3%, <i>p</i> = 0.048) in patients with a family history of HBV infection in both mothers and siblings whose HBV were considered to be transmitted vertically. There was a negative correlation between maternal age at birth and patient age in this group, reflecting the fact that the age of childbearing is increasing recently in Japan. Because patients with HBV/B experience hepatitis B e antigen seroconversion at an earlier age, it was considered that HBV/B has become harder to transmit vertically in recent decades.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The recent decrease in vertical transmission of HBV/B associated with an older childbearing age in Japan might be one of the reasons for the finding that HBV/B patients were older than HBV/C patients.</p>\u0000 </section>\u0000 </div>","PeriodicalId":12987,"journal":{"name":"Hepatology Research","volume":"55 5","pages":"773-779"},"PeriodicalIF":3.9,"publicationDate":"2025-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/hepr.14169","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143902825","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to “Therapeutic efficacy of lenvatinib as third-line treatment after regorafenib for unresectable hepatocellular carcinoma progression”","authors":"","doi":"10.1111/hepr.14167","DOIUrl":"https://doi.org/10.1111/hepr.14167","url":null,"abstract":"<p>Hiraoka A, Kumada T, Hatanaka T, Tada T, Kariyama K, Tani J, et al. Therapeutic efficacy of lenvatinib as third-line treatment after regorafenib for unresectable hepatocellular carcinoma progression. <i>Hepatology Research</i>. 2021; 51: 880–9. https://doi.org/10.1111/hepr.13644.</p><p>In the “Methods” section of the abstract, the text “From June 2017 to October 2020, 63 patients with Child–Pugh A and treated with regorafenib followed by sorafenib were enrolled…” was incorrect.</p><p>This should have read: “From June 2017 to October 2020, 63 patients with Child–Pugh A and treated with sorafenib followed by regorafenib were enrolled…”</p><p>We apologize for this error.</p>","PeriodicalId":12987,"journal":{"name":"Hepatology Research","volume":"55 5","pages":"781"},"PeriodicalIF":3.9,"publicationDate":"2025-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/hepr.14167","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143902856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to “Switching from combination therapy with entecavir hydrate plus tenofovir alafenamide fumarate to tenofovir alafenamide fumarate monotherapy in patients with chronic hepatitis B based on nucleotide sequences of hepatitis B virus pregenome RNA”","authors":"","doi":"10.1111/hepr.14166","DOIUrl":"https://doi.org/10.1111/hepr.14166","url":null,"abstract":"<p>Yamada S, Uchida Y, Kouyama JI, et al. Switching from combination therapy with entecavir hydrate plus tenofovir alafenamide fumarate to tenofovir alafenamide fumarate monotherapy in patients with chronic hepatitis B based on nucleotide sequences of hepatitis B virus pregenome RNA. <i>Hepatol Res</i>. 2024;54:877-887.</p><p>In the “ETHICS STATEMENTS” section, the text “The study adhered to the ethical guidelines of the Declaration of Helsinki and was conducted with the approval of the Institutional Review Board of Saitama Medical University Hospital (2022-017).” was incorrect. This should have read: “The study adhered to the ethical guidelines of the Declaration of Helsinki and was conducted with the approval of the Institutional Review Board of Saitama Medical University Hospital (19026.01 and 2022-017).”</p><p>We apologize for this error.</p>","PeriodicalId":12987,"journal":{"name":"Hepatology Research","volume":"55 5","pages":"780"},"PeriodicalIF":3.9,"publicationDate":"2025-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/hepr.14166","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143902857","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pancreatic congestion is associated with exocrine pancreatic function in liver cirrhosis","authors":"Masahito Kokubu,&nbsp;Yoshiki Imamura,&nbsp;Teru Kumagi,&nbsp;Masashi Hirooka,&nbsp;Yuki Numata,&nbsp;Yusuke Okujima,&nbsp;Sho Ishikawa,&nbsp;Kaori Marui-Sato,&nbsp;Mitsuhito Koizumi,&nbsp;Yoichi Hiasa","doi":"10.1111/hepr.14165","DOIUrl":"https://doi.org/10.1111/hepr.14165","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>Portal hypertension resulting from liver cirrhosis (LC) can lead to pancreatic congestion and impaired insulin secretion. Therefore, this prospective study aimed to assess the association between pancreatic congestion and exocrine pancreatic function in patients with LC.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>In our clinical study, pancreatic congestion and exocrine pancreatic function were evaluated using shear wave dispersion (SWD) and fecal elastase-1 (FE-1). Additionally, pancreatic acinar cells, venous walls, and fibrosis were assessed in an autopsy study.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The FE-1 levels were lower in the LC group (<i>n</i> = 41) than in the control group (<i>n</i> = 41) (312 ± 89 vs. 442 ± 100 μg/g, <i>p</i> &lt; 0.001). The LC group included six patients (14.6%) with exocrine pancreatic insufficiency, whereas there were none in the control group. Pancreatic SWD values were significantly higher in the LC group than in the control group (14.8 ± 2.3 vs. 10.0 ± 1.28 [m/s]/kHz, <i>p</i> &lt; 0.001). Fecal elastase-1 was significantly negatively correlated with pancreatic SWD (<i>R</i> = −0.55, <i>p</i> &lt; 0.001). As for the autopsy study, the percentage of the trypsin-positive area was significantly lower in the LC group (<i>n</i> = 11) than in the control group (<i>n</i> = 10) (38.1 ± 10.1% vs. 26.5 ± 3.0%, <i>p</i> = 0.0055). The percentage of trypsin-positive area was significantly negatively correlated with the wall thickness of the pancreatic vein (<i>R</i> = −0.76, <i>p</i> &lt; 0.001).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Exocrine pancreatic function was reduced and significantly correlated with pancreatic congestion in patients with LC. Portal hypertension may affect the exocrine pancreatic function.</p>\u0000 </section>\u0000 </div>","PeriodicalId":12987,"journal":{"name":"Hepatology Research","volume":"55 5","pages":"685-695"},"PeriodicalIF":3.9,"publicationDate":"2025-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/hepr.14165","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143902817","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Changes in serum myostatin levels among patients with type C liver cirrhosis treated with direct-acting antivirals","authors":"Tomoyuki Suehiro,&nbsp;Hideko Kozuru,&nbsp;Kosuke Matusmoto,&nbsp;Yuki Kugiyama,&nbsp;Yasuhide Motoyoshi,&nbsp;Akira Saeki,&nbsp;Shinya Nagaoka,&nbsp;Kazumi Yamasaki,&nbsp;Atsumasa Komori,&nbsp;Hiroshi Yatsuhashi","doi":"10.1111/hepr.14162","DOIUrl":"https://doi.org/10.1111/hepr.14162","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>To clarify whether direct-acting antiviral treatment improves serum myostatin levels of patients with cirrhosis caused by hepatitis C virus.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A total of 99 patients with type C liver cirrhosis were administered direct-acting antiviral treatment. The median age was 73 years, and 58 patients were women. We measured the levels of serum myostatin, decorin, follistatin, and insulin-like growth factor-1, as well as the skeletal muscle mass index at baseline. We measured the sustained virological response at 48 weeks.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Serum myostatin levels of the Child–Pugh class B or C group (<i>n</i> = 30) were significantly higher than those of the Child–Pugh class A group (<i>n</i> = 69) at baseline. The multivariate analysis indicated that the total bilirubin level and Mac-2 binding protein glycosylation isomer level were independent factors associated with serum myostatin levels. Serum myostatin levels significantly decreased, whereas the skeletal muscle mass index and insulin-like growth factor-1 level were significantly increased at 48 weeks.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Direct-acting antiviral treatment decreased serum myostatin levels and may improve sarcopenia in patients with cirrhosis.</p>\u0000 </section>\u0000 </div>","PeriodicalId":12987,"journal":{"name":"Hepatology Research","volume":"55 5","pages":"631-637"},"PeriodicalIF":3.9,"publicationDate":"2025-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/hepr.14162","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143902867","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of weight loss and improvement of steatotic liver disease using magnetic resonance imaging in patients with metabolic dysfunction associated steatotic liver disease","authors":"Yuichiro Suzuki,&nbsp;Shinya Maekawa,&nbsp;Leona Osawa,&nbsp;Yasuyuki Komiyama,&nbsp;Hitomi Takada,&nbsp;Masaru Muraoka,&nbsp;Mitsuaki Sato,&nbsp;Shinichi Takano,&nbsp;Hiroyuki Morisaka,&nbsp;Hiroshi Onishi,&nbsp;Nobuyuki Enomoto","doi":"10.1111/hepr.14163","DOIUrl":"https://doi.org/10.1111/hepr.14163","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>Weight loss (WL) is important for improving steatotic liver. However, there have been no sufficient reports comparing WL with liver fibrosis and steatotic changes using magnetic resonance imaging (MRI).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The study included 111 patients with metabolic dysfunction associated steatotic liver disease who did not take any new drugs during the study period. They were evaluated using MRI and FibroScan®, and then were given a mild low-carbohydrate diet. One year later, they were evaluated again, and changes in alanine transaminase (ALT), MRI proton density fat fraction (MRI-PDFF), and magnetic resonance elastography were examined.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The patients achieved an average WL of 4.2 kg. MRI-PDFF was significantly improved by 0.68-fold for 5%–7% WL, 0.61-fold for 7–10 %WL, and 0.35-fold for 10% or more WL (vs. gain: <i>p</i> &lt; 0.01). In patients with a WL of 5% or more, magnetic resonance elastography was decreased. MRI-PDFF reduction of 30% was observed in 56% of patients with 5%–7% WL, 75 % with 7%–10% WL, and 94% with 10% or more WL (<i>p</i> &lt; 0.01). ALT normalization or 30% reduction was well associated with WL, with 73% for 5%–7% WL, 64% for 7%–10% WL, and 93% for 10% or more WL (<i>p</i> &lt; 0.01). The optimal cutoff for MRI-PDFF improvement and ALT improvement was 5.3% WL in both tests according to receiver operating characteristic analysis (<i>p</i> &lt; 0.01).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Many patients achieved improvement in MRI-PDFF and ALT with WL. WL of 5.3% can improve MRI-PDFF and ALT, contributing to a better prognosis for metabolic dysfunction associated steatotic liver disease patients.</p>\u0000 </section>\u0000 </div>","PeriodicalId":12987,"journal":{"name":"Hepatology Research","volume":"55 5","pages":"638-647"},"PeriodicalIF":3.9,"publicationDate":"2025-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/hepr.14163","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143902866","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}